Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial

Schöllhammer, M.; Brenaut, E.; Ménard-Andivot, N.; Pillette-Delarue, M.; Zagnoli, Anne; Lay, M. Chassain-Le; Sassolas, B.; Jouan, N.; Ru, Yi; Abasq‐Thomas, C.; Greco, Maurizio; Penven, K.; Roguedas-Contios, A.-M.; Dupré-Goetghebeur, D.; Gouedard, Cédric; Miséry, Laurent; Gal, Grégoire Le

doi:10.1111/bjd.13973

Cited by 49 publications

(45 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results were consistent across each study type, for each anticholinergic drug and none of the studies recorded a worsening in QOL following anticholinergic therapy. Placebo therapy was also associated with a modest improvement in QOL outcome, but the effect was not comparable to anticholinergic therapy . The mean proportion of patients who experienced improvement in QOL was 75.6% (range 57.6–100%), and these improvements were maintained at long‐term follow‐up …”

Section: Resultsmentioning

confidence: 97%

“…All of the studies documented evidence of dry mouth, and results were consistent between different drug therapies and patient cohorts. Placebo also caused symptoms of dry mouth, but these effects were not comparable to high‐dose anticholinergic therapy . Dry mouth was dose related and more common with oxybutynin therapy 10 mg/day or more .…”

Section: Resultsmentioning

confidence: 99%

“…Palpitations suffered by one patient during oxybutynin therapy were not confirmed by medical investigation . Only 14 (63.6%) of the studies which recorded rates of adverse events monitored adverse events additional to dry mouth . It is unclear whether studies had not screened for other adverse events, or whether they had not occurred.…”

Section: Discussionmentioning

confidence: 97%

“…Quality of life is dependent on both disease severity and individual adaptation. Placebo therapy may also mitigate stress and anxiety‐related sweating and consequently be responsible for a modest improvement in QOL outcome …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Cruddas

Baker

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off-license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326). MEDLINE, EMBASE and PubMed were searched from 1946 to 2015. Inclusion criteria included observational and experimental studies, anticholinergic medication use in primary hyperhidrosis, oral therapy and clear diagnostic and outcome measures. Twenty-three articles relevant to the inclusion criteria were analysed. Oxybutynin therapy improved symptoms in an average of 76.2% (range 60-97%) patients and improved QOL in 75.6% (range 57.6-100%) of patients. Methantheline bromide therapy was associated with a 41% reduction in axillary sweating, 16.4% reduction in palmar sweating, 25% decrease in HDSS score and 40.9% increase in DLQI score. Outcome measures of glycopyrrolate therapy were too variable to collate. Dry mouth was reported in 73.4% (range 43.3-100%) of participants taking oxybutynin 10 mg/day, 38.6% (range 27.8-63.2%) of patients taking glycopyrrolate and 68.8% of patients taking methantheline bromide. Nine studies reported that patients stopped therapy due to adverse events. In eight of these studies, a mean of 10.9% of total participants ceased treatment due to dry mouth. Evidence of oral anticholinergic therapy for hyperhidrosis is limited. However, its use is associated with improvement in quality of life and clinical symptoms but at the cost of considerable adverse events.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Cruddas

Baker

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…A prospective, randomized, placebo-controlled trial for the initial treatment of hyperhidrosis showed improvement in greater than 70% of patients with palmar and axillary hyperhidrosis and greater than 90% of patients with plantar hyperhidrosis [35]. A subsequent study showed a 60% improvement in the Hyperhidrosis Disease Severity Scale and a significant improvement in the Dermatology Life Quality Index [36]. Dosing in the literature varies greatly from 2.5 to 5 mg twice daily with dry mouth being the main dose-limiting adverse event [35, 37].…”

Section: Current Therapies For Hyperhidrosismentioning

confidence: 99%

Current and Emerging Medical Therapies for Primary Hyperhidrosis

Grabell

Hebert

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Hyperhidrosis is defined as the production of sweat beyond what is physiologically necessary to maintain thermal homeostasis. This disease state may (and typically does) have a significant impact on the patient’s quality of life. Medications including antiperspirants, anticholinergics, and botulinum toxin have been shown to be effective in the management of hyperhidrosis. Several medical device technologies have also proven to be effective. This review article will explore the current and emerging pharmacological and medical device treatments for hyperhidrosis and provide a framework for treating patients who suffer with primary forms of hyperhidrosis.

show abstract

Overmatig zweten (primaire lokale hyperhidrosis)

Vries¹

2017

Therapie Van Alledaagse Klachten

View full text Add to dashboard Cite

Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial

Abstract: Treatment with low-dose oxybutynin is effective in reducing symptoms of hyperhidrosis in generalized or localized forms. Side-effects were frequent but minor and mainly involved dry mouth.

Cited by 49 publications

References 28 publications

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Current and Emerging Medical Therapies for Primary Hyperhidrosis

Overmatig zweten (primaire lokale hyperhidrosis)

Contact Info

Product

Resources

About